Applying Pharmacogenomic Guidelines to Combat Medical Care
Open Access
- 30 December 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 187 (Supplement) , 18-24
Abstract
Pharmacogenomics is a pillar of personalized medicine that has the potential to deliver optimized treatment in many medical settings. Military medicine in the deployed setting is unique and therefore warrants separate assessment pertaining to its potential capabilities and impact. Pharmacogenomics for United States Active Duty Service Members medical care in the deployed setting has not, to our knowledge, been previously reviewed. We present potential applications of pharmacogenomics to forward medical care through two comprehensive references for deployed medical care, the Tactical Combat Casualty Care Guidelines (TCCC) and Emergency War Surgery (EWS) fifth edition. All drugs within the deployment manuals, TCCC guidelines and EWS book, were identified and the list was cross-referenced to the Clinical Pharmacogenetics Implementation Consortium guidelines and genes–drugs interactions list as well as the Food and Drug Administration Table of Pharmacogenomics Biomarkers in Drug Labeling. Ten pharmacologic categories were identified, consisting of 15 drugs, along with the classes, aminogylcosides, beta-blockers, and volatile anesthetics. Drugs and pharmacogenomics liabilities were tabulated. Eight specific drugs or classes are expounded upon given the belief of the authors of their potential for impacting future treatment on the battlefield in the setting of prolonged field care. This review outlines several genes with liabilities in the prolonged field care setting and areas that may produce improved care with further study.Keywords
This publication has 34 references indexed in Scilit:
- CYP2D6- and CYP3A-Dependent Enantioselective Plasma Concentrations of Ondansetron in Postanesthesia CareAnesthesia & Analgesia, 2011
- Amitriptyline and Prochlorperazine Inhibit Proinflammatory Mediator Release From Human Mast CellsJournal of Clinical Psychopharmacology, 2011
- Nonfreezing Cold-Induced InjuriesJournal of the Royal Army Medical Corps, 2011
- Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokineticsJournal of Clinical Pharmacy and Therapeutics, 2011
- Cardiovascular Risk Factors in Deployed Service Members With and Without Acute Coronary SyndromesJournal of Cardiovascular Nursing, 2011
- Effects ofCYP2C9*1/*13on the pharmacokinetics and pharmacodynamics of meloxicamBritish Journal of Clinical Pharmacology, 2010
- ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”Circulation, 2010
- Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleedingPharmacogenetics and Genomics, 2008
- The Impact of Pharmacogenomics on Postoperative Nausea and VomitingAnesthesiology, 2005
- Pharmacogenetics of oral anticoagulantsPharmacogenetics, 2003